Form 4: ASMB CSO Granted 26,000 RSUs, Plan Amendment Pending

Assembly Biosciences' Chief Scientific Officer, William E. Delaney IV, was granted 26,000 restricted stock units, with a portion contingent on stockholder approval of a plan amendment.

Summary

• William E. Delaney IV, Chief Scientific Officer of Assembly Biosciences, Inc. (ASMB), was granted 26,000 restricted stock units (RSUs) on March 29, 2026.
• The RSUs vest in four equal annual installments, beginning March 29, 2027, and continuing through March 29, 2030, assuming continuous service.
• This grant represents 65% of the reporting person's annual equity grant.
• The remaining 35% of the annual equity grant is contingent upon stockholder approval of an amendment to the Issuer's Amended and Restated 2018 Stock Incentive Plan to increase the number of authorized shares.
• Following this transaction, William E. Delaney IV beneficially owns 45,642 shares of common stock.
• The beneficial ownership includes 2,909 shares acquired under the Assembly Biosciences, Inc. Second Amended and Restated 2018 Employee Stock Purchase Plan on May 14, 2025.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive event, reflecting standard executive compensation and retention efforts, though the contingency on stockholder approval for a portion of the grant introduces a minor element of uncertainty.

Positives

• The grant of restricted stock units aligns the Chief Scientific Officer's interests with long-term shareholder value through equity ownership.
• The vesting schedule incentivizes continuous service and retention of a key executive.

Negatives

• A portion (35%) of the Chief Scientific Officer's annual equity grant is contingent on future stockholder approval of an amendment to the stock incentive plan, introducing uncertainty for that part of the compensation.

Risks

• Stockholder approval risk: The remaining 35% of the annual equity grant is contingent on stockholders approving an amendment to the 2018 Stock Incentive Plan to increase authorized shares. Failure to obtain approval could impact executive compensation and potentially future equity grants.

Future Outlook

The future outlook includes the vesting of restricted stock units over the next four years, contingent on continuous service. A portion of the annual equity grant is also contingent on future stockholder approval of an amendment to the company's stock incentive plan.

Industry Context

StockSavvy.ai notes that the grant of restricted stock units to a Chief Scientific Officer is a standard practice in the biotechnology and pharmaceutical industries for executive compensation, aiming to attract, retain, and motivate key talent by aligning their long-term interests with company performance.

Comparison to Industry Standards

• Equity compensation, particularly through restricted stock units with multi-year vesting, is a common practice across the biotechnology sector, comparable to compensation structures seen at companies like Moderna, BioNTech, or Gilead Sciences, designed to incentivize long-term commitment and performance.
• The contingency of a portion of the grant on stockholder approval for an increase in authorized shares is also a standard governance procedure when existing share pools are nearing depletion, ensuring compliance and proper oversight.

Corporate Governance

Stakeholder Impact

• Shareholders: Potential for minor dilution if the stock incentive plan amendment is approved and additional shares are issued. However, the grant also aligns executive interests with long-term shareholder value.
• Employees: The Employee Stock Purchase Plan (ESPP) allows employees to acquire shares, fostering broader employee ownership and alignment.

Next Steps

• The company will need to seek stockholder approval for an amendment to the Amended and Restated 2018 Stock Incentive Plan to increase the number of shares authorized for issuance.
• The granted restricted stock units will vest in four equal installments on March 29, 2027, 2028, 2029, and 2030, subject to continuous service.

Key Dates

Recommendation

This Form 4 filing details a routine equity grant to a key executive and does not present information significant enough to alter an existing investment thesis or recommendation. It reflects standard compensation practices and executive retention efforts, which are generally factored into a company's valuation.

Keywords

Assembly Biosciences, ASMB, Restricted Stock Units, RSU Grant, Insider Transaction, Form 4, Equity Compensation, Chief Scientific Officer, Stock Incentive Plan